dr. mesa on unanswered questions regarding jak inhibitors in myelofibrosis
Published 4 years ago • 72 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
0:58
dr. mesa on challenges with jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:42
dr. mesa on jak inhibitors in the pipeline for myelofibrosis
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
1:30
dr. michaelis on unanswered questions in myelofibrosis treatment
-
1:05
dr. mesa on rechallenging with jak inhibitor therapy in mpns
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
2:43
dr. tefferi on the outlook for jak inhibitors in myelofibrosis
-
1:12
evidence supports rechallenging of jak inhibitors in myelofibrosis
-
5:34
treating with a jak inhibitor for myelofibrosis
-
1:01
dr. masarova on the safety of jak inhibitor/targeted therapy combos in myelofibrosis
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
6:21
novel jak inhibitor pacritinib proves effective for easing symptoms of myelofibrosis
-
3:23
myelofibrosis: updates on jak inhibitors
-
1:30
dr. oh discusses the differences between investigational jak inhibitors and ruxolitinib in mpns
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
1:08
investigators study jak inhibitors in patients with myelofibrosis